Cellectar Biosciences, Inc. (CLRB) financial statements (2021 and earlier)

Company profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments57111310114
Cash and cash equivalents57111310114
Other undisclosed current assets111110
Total current assets:58111411124
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment001012
Long-term investments and receivables001   
Long-term investments001   
Intangible assets, net (including goodwill)   222
Goodwill   222
Other noncurrent assets000000
Total noncurrent assets:111233
TOTAL ASSETS:59121513158
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:332211
Accounts payable111   
Accrued liabilities000   
Employee-related liabilities100   
Other undisclosed accounts payable and accrued liabilities110211
Debt 00000
Deferred rent credit  0
Derivative instruments and hedges, liabilities  0005
Deferred revenue and credits0  
Other undisclosed current liabilities0     
Total current liabilities:432226
Noncurrent Liabilities
Long-term debt and lease obligation00 000
Long-term debt, excluding current maturities     0
Capital lease obligations 000
Operating lease, liability00
Liabilities, other than long-term debt  0 00
Deferred revenue and credits 00
Deferred rent credit  0
Other undisclosed noncurrent liabilities(0)     
Total noncurrent liabilities:000000
Total liabilities:432226
Stockholders' equity
Stockholders' equity attributable to parent, including:5591311142
Preferred stock    1 
Common stock000000
Additional paid in capital162120108948366
Accumulated deficit(127)(112)(98)(84)(71)(65)
Other undisclosed stockholders' equity attributable to parent20131  
Total stockholders' equity:5591311142
TOTAL LIABILITIES AND EQUITY:59121513158

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:  (0)  (0)
Operating expenses(15)(14)(13)(14)(9)(9)
Operating loss:(15)(14)(13)(14)(9)(9)
Nonoperating income000033
Investment income, nonoperating 00034
Interest and debt expense0   (0)(0)
Net loss:(15)(14)(13)(14)(6)(5)
Other undisclosed net income (loss) attributable to parent(0)   00
Net loss attributable to parent:(15)(14)(13)(14)(6)(5)
Preferred stock dividends and other adjustments  (2)(1)  
Net loss available to common stockholders, diluted:(15)(14)(15)(15)(6)(5)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(15)(14)(13)(14)(6)(5)
Comprehensive loss, net of tax, attributable to parent:(15)(14)(13)(14)(6)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: